China NMPA Drug Inspection - Shijiazhuang Berlin Herbal Medicine Processing Plant - Tulip

The Hebei Provincial Drug Administration issued Drug Quality Bulletin No. 3 on November 12, 2020, detailing findings from its 2020 supervision and sampling inspection plan. The report highlights quality failures at two specific pharmaceutical entities: Anguo Shenhao Pharmaceutical Co., Ltd. and Shijiazhuang Bailin Medicinal Herbs Processing Plant. Specifically, a batch of Earthworm from Anguo Shenhao and a batch of Turmeric from Shijiazhuang Bailin were found to be non-compliant after testing by the Qinhuangdao Municipal Food and Drug Inspection Center. Both products failed the required appearance standards due to partial insect infestation in samples collected from the Longjiadian Town Health Center. Operating under the Drug Administration Law of the People's Republic of China, regulatory authorities have initiated enforcement actions including the sealing and seizure of the substandard products. The administration has mandated formal investigations into these enterprises for the illegal production and sale of inferior drugs. Furthermore, necessary risk control measures must be implemented, and any evidence of counterfeit activity or criminal conduct must be referred to public security departments for prosecution. All relevant findings are to be reported to the Inspection Department of the Hebei Provincial Drug Administration.